Error loading player: No playable sources found
320
Castrate Resistant Prostate Cancer: The New Frontier in Treatment
Date
October 14, 2013
Credits
1.25 CH | 1.25 Rx | 1 CME | Expired October 15, 2015
$20
Standard Price
In the last few years, advances in pharmacotherapy and immunotherapy have given new hope in castrate resistant prostate cancer with increases in overall survival up to 5.6 months. Advanced practice providers and nurses need to have an understanding of these treatments. This lecture will cover abiraterone, enzalutamide, sipuleucel-t, radium 223, docetaxel and cabazitaxel. There will also be discussion on current clinical trials showing promise.
Contact hours available until 10/11/2015.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.
Faculty, Planners, and Authors Conflict of Interest Disclosure:
Planning Commitee Disclosures:
Lee Ann Boyd, MSN, ARNO-C, CUNP / Presenter Bureau :Warner Chilcott
Leanne Schimke, MSN, CRNP-C CUNP/ Presenter :Amgen-Xgeva, Warner Chilott
Speaker disclosures:
Leanne Schimke, MSN, CRNP-C, CUNP
Presenter: Amgen-Xgeva, Warner Chilcott-Enablex
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
Contact hours available until 10/11/2015.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.
Faculty, Planners, and Authors Conflict of Interest Disclosure:
Planning Commitee Disclosures:
Lee Ann Boyd, MSN, ARNO-C, CUNP / Presenter Bureau :Warner Chilcott
Leanne Schimke, MSN, CRNP-C CUNP/ Presenter :Amgen-Xgeva, Warner Chilott
Speaker disclosures:
Leanne Schimke, MSN, CRNP-C, CUNP
Presenter: Amgen-Xgeva, Warner Chilcott-Enablex
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
- Discuss prostate cancer disease progression and identify the new drugs currently available and promising research for the treatment of castrate resistant prostate cancer.
- Indicate the appropriate monitoring of individuals on abiraterone.
- Describe how Sipuleucel-T is given and possible side effects that may be encountered.
Speaker
Leanne S. Schimke, MSN, CRNP, FNP-C, CUNP
Nurse Practitioner
Specialties
Related Products
The Aging Underactive Bladder
This presentation will provide discussion of the aging underactive bladder in the elderly and risk factors associated with an underactive bladder. Underactive bladder and current standards will be discussed including definition, causes, and treatments as they pertain to the elderly…
Palliative Primer for Pain, Anorexia and Nausea Management
This presentation will begin with a brief overview of palliative care and how it differs from hospice. We will explore language to use with your urological cancer patients when curative treatment may no longer be appropriate…
Evidence-Based Preparation for Prostate Biopsy: UK Perspective
Presenters will discuss the evidence-base for preparing the patient in terms of antibiotic prophylaxis, analgesia, cleansing enema, bowel preparation and the evidence for the equipment (disposables) required…
Painful Bladder Syndrome/Interstitial Cystitis
This lecture will provide advanced practice providers with the most current clinical information on managing painful bladder syndrome/interstitial cystitis. A review of current trends in pharmacological treatments will also be included…
